Actionable news
All posts from Actionable news
Actionable news in TBPH: THERAVANCE BIOPHARMA Inc,

Theravance and Mylan announce positive results from late-stage studies of COPD candidate revefenacin; U.S. marketing application planned by end of 2017

Theravance (NASDAQ:TBPH) and development partner Mylan N.V. (NASDAQ:MYL) report successful results from two replicate Phase 3 clinical trials assessing revefenacin (TD-4208) for the treatment of chronic obstructive pulmonary disease (COPD). Both studies met their primary endpoint of a statistically valid improvement versus placebo in trough forced...